Androgen signaling drives prostate cancer progression and is a therapeutic target.
Introduction
Androgen signaling drives prostate cancer development and progression. Endogenous androgens, testosterone and dihydrotestosterone, bind to the intracellular androgen receptor (AR) which translocates to the nucleus. The AR functions as a transcription factor and activates downstream signaling pathways associated with proliferation, invasion and metabolism [1] . Androgen deprivation therapy (ADT) inhibits AR signaling by blocking the production of androgens or by inhibiting androgen binding to the AR. ADT is used to treat localized, locally advanced and metastatic disease and an estimated 50% of prostate cancer patients receive ADT [2] . Although ADT is initially effective, resistance subsequently develops and the AR signaling pathway remains active even in the absence of endogenous androgens. The development of androgen independent or castrate-resistant prostate cancer (CRPC) is associated with the presence of metastases and a rapid clinical demise [3] .
Identifying which patients will progress to CRPC is a major challenge in the treatment of prostate cancer. Understanding the biology that underpins progression to CRPC will support the development of novel strategies to identify, prevent and treat CRPC.
Mechanisms thought to contribute to AR activity in CRPC include gene amplification, activating mutations and cross-talk with other signaling pathways such as the hypoxia inducible factor (HIF) pathway [4] . HIF is a heterodimer, consisting of a constitutively stable HIF1b and a tightly regulated HIF1a subunit. Under oxygenated conditions, the HIF1a protein is ubiquitinated and rapidly degraded. In the absence of oxygen, HIF1a is stabilized and dimerizes with HIF1b subunits to form an active HIF transcription complex. HIF translocates to the nucleus and induces the expression of genes associated with metabolism, angiogenesis, invasion and cell survival. Hypoxia-independent stabilization can also occur-a condition referred to as pseudohypoxia [5] [6] . Expression of HIF is associated with increased risk and a poor prognosis in prostate cancer [7, 8] .
Crosstalk between the AR and hypoxia/HIF has been reported. ADT in hypoxia promotes adaptive androgen/AR-independence, and confers resistance to androgen/AR-targeted therapy (Geng et al 2018) . Co-immunoprecipitation assays have confirmed a direct interaction between AR and HIF1a, and ChIP analysis showed HIF1a interacts with the AR on the PSA gene promoter [9] . Hypoxia induced activation of HIF can also increase expression of the AR [10, 11] . As AR and HIF signaling pathways are major signaling hubs and oncogenic drivers of prostate cancer progression, this study aimed to investigate further the relationship between them. Here we report for the first time that combined AR and HIF1a signaling in vivo promotes tumor growth and demonstrate the capacity of HIF1a to promote tumor growth in the absence of endogenous androgen in vivo. We also show that the AR and HIF/hypoxia signaling pathways function independently regulating the transcription of different subsets of genes with few shared targets.
Materials and methods

Cell culture
LNCaP, LNCaP-Bic, LNCap-OHF and PC3 cell lines (and the corresponding stable transfectants) were cultured in RPMI with glutamine and 10% fetal calf serum. For hypoxia experiments, cells were exposed to 1% oxygen using either a hypoxic workstation (INVIVO2, Ruskinn, Leeds, UK) or a hypoxic incubator. For AR signaling experiments, LNCaP cells were grown in charcoal stripped serum for 96 h prior to adding synthetic androgen (R1881) or vehicle control (ethanol).
Infection of HIF1a retroviral vectors
A model of pseudohypoxia was established in androgen-sensitive LNCaP cells by viral transfection of a vector encoding HIF1a with two amino acid substitutions which prevented its degradation in the presence of oxygen. Viral supernatants were prepared by transfecting the Phoenix packaging cell line (Orbigen, San Diego, CA) using Lipofectamine 2000 (Life Technologies, Paisley, UK). After initial transfection, Phoenix cells were grown at 32°C. The supernatant was collected and filtered (0.45 μm), then supplemented with a 1:4 volume of fresh medium with 7.5 μg/mL Polybrene (Sigma, Poole, UK), and added to LNCaP cells plated on p100 dishes at 30-40% confluence. After 20 h, cells were washed, and fresh media added for 20 h before a second round of transfection and G418 selection. The constitutively active form of HIF1a (carrying two substitutions: P402A and P564A) was cloned into pBMN-I-EGFP.
Western blot analysis
Cell lysis involved urea-SDS buffer supplemented with phenylmethylsulfonyl fluoride (PMSF) as previously described [1] .
Immunoblots were visualized with enhanced chemiluminescence reagent or enhanced chemiluminescence plus reagent (Amersham, Arlington Heights, IL). Antibodies used were HIF1a (clone 54, Transduction Labs, Lexington KY) and α tubulin (CRUK).
Xenograft experiments
Xenograft tumors were generated with LNCaP/Empty and LNCaP/HIF1-clone 1 cells that stably expressed a fusion protein of luciferase and yellow fluorescent protein (YFP). There 
Clinical material and immunohistochemistry
Clinical samples were collected from Cambridge University Hospitals NHS Trust as part of the PROMPT study, and ethical approval was granted by the local research and ethics committee (LREC number: 02/281M) and by the multicenter research and ethics committee (MREC number 01/4061). A tissue microarray (TMA) was constructed, consisting of at least two tumor cores with matched benign prostate tissue cores from each of 41 patients with CRPC. Sections 3 μm thick were mounted on Snowcoat X-tra slides (Surgipath, Richmond, IL), dewaxed in xylene and rehydrated using graded ethanol washes. For antigen retrieval, sections were immersed in preheated DAKO target retrieval solution and treated for 90 s in a pressure cooker (DAKO, Glostrup, Denmark) . Antigen/antibody complexes were detected using the DAKO catalyzed signal amplification (CSA) system according to the manufacturer's instructions. Sections were counterstained with hematoxylin for 30 s, dehydrated in graded ethanol washes and mounted (Lamb, London, UK). A rabbit pAb was used for HIF1a immunohistochemistry in the xenograft tumors (#NB 100-479, Novus Biologicals, Oxford, UK) and a mouse mAb was used for HIF1a immunohistochemistry in the CR-TMA (H1α67 # NB 100-105, Novus Biologicals). Immunohistochemistry staining was scored by two independent blinded assessors as 1 (negative), 2 (<25% of nuclei staining), 3
(25-50% of nuclei staining), 4 (majority of cells -weak staining), 5 (majority of cellsmoderate staining) and 6 (majority of cells -strong staining).
Illumina HumanWG v2 BeadArray data analysis
LNCaP, LNCaP/Empty and LNCap/HIF1a clone 1 cells were grown in charcoal stripped serum for 96 h prior to adding 1 nM R1881 or 0.01% ethanol (vehicle control) for 4 h and extracting RNA. For hypoxia experiments, LNCaP cells were exposed to 1% hypoxia or normoxia for 24 h prior to RNA extraction. Gene expression data were generated using the Illumina HumanWGv2 BeadArrays. After background correction, normalization and log2 transformation, differential expression analysis was performed with LIMMA on probe set level. Probe sets with bad and no match probe scores were omitted from analysis. False discovery rate adjusted P value of 0.05 and 1.5 fold change were applied as cut-off.
Chromatin Immunoprecipitation
ChIP and re-ChIP was performed as previously described [12, 13] . Cells were cultured in phenol red-free RPMI media supplemented with 10% charcoal dextran-stripped FBS for 72 h before adding 1 nM R1881 or 0.01% ethanol for 4 h. For hypoxic experiments, cells were placed in a hypoxic incubator at 1% oxygen for 12 h prior to adding R1881 or ethanol. AR (AR N20, Sc-816X, Santa Cruz), HIF1a (ab2185, Abcam), Diagenode) and H3K4me3 (pAb 003-050, Diagenode, Seraing, Belgium) antibodies were used in the assay. ChIP enrichment was tested by real-time PCR and the remainder was used for single-end SOLEXA library preparation.
ChIP-seq SOLEXA library preparation
Single-end SOLEXA sequencing libraries were prepared as previously described [13] .
Sequence reads were generated using an Illumina Genome Analyzer II and mapped to the reference human genome before peak calling. Called peaks were analysed in R using
ChIPpeakAnno package [14] .
Data deposition
Microarray and ChIP-seq data generated have been deposited within the National Center Table I ). For TCGA, GSE54460, GSE70770, GSE16560 gene expression data were downloaded directly. For GSE21032, raw CELL files were downloaded and processed using aroma package.
Biochemical recurrence free (BCR) survival was the primary endpoint, except for Sboner where only overall survival was available. Patients were stratified into high and low groups based on cohort median expression of the gene of interest. Survival estimates were performed using the Kaplan-Meier method. The log-rank test was used to test the null hypothesis of equality of survival distributions. Hazard ratios (HR) and 95% confidence intervals (CI) were obtained using the Cox proportional hazard model.
Results
HIF1a expression promotes proliferation and resistance to ADT in vitro and in vivo
The stable overexpression of HIF1a in LNCaP/HIF1a clone 1 and clone 2 (Supplementary Fig 1A) cells increased proliferation and resistance to ADT (bicalutamide) in vitro (Fig 1) .
Growth rate decreased in response to ADT in LNCaP/Empty but not LNCaP/HIF1a cells.
HIF1a expression was also detected in normoxia in ADT resistant (LNCaP-Bic, LNCaP-OHF) and androgen-independent (PC3) cells but not in androgen sensitive (LNCaP) cells ( Supplementary Fig 1) . LNCaP/HIF1a xenografts grew faster than the LNCaP/Empty tumors, and were resistant to ADT (castrated mouse model; Fig 2) .
Castrate resistant prostate cancers have high HIF1a expression
HIF1a immunohistochemistry showed high levels of HIF1a expression in CRPC. All CRPC biopsies expressed HIF1a in comparison with only 57% of benign tumors. Sixty-eight percent of CRCP biopsies had strong HIF1a staining compared with just 8% of benign tissue ( Supplementary Fig 2) .
Only seven genes upregulated by both androgen and HIF1a
In (Table I ). The number of AR binding sites increased with androgen treatment and decreased in hypoxia. However, while hypoxia almost halved the number of AR binding sites, they increased when androgen was added under hypoxia (from 18,404 to 45,635) suggesting an interplay between hypoxia and androgen signalling at the level of AR recruitment to chromatin. AR binding sites were highly conserved between the vehicle control and androgen treated cells exposed to normoxia (86%) and hypoxia (79%) ( Fig 4A) .
As expected hypoxia increased the number of HIF binding sites, the greatest number of HIF binding sites was observed in cell treated with combined hypoxia and androgen treatment ( H3K4me1 is enriched at active and primed enhancers and H3K4me3 in a promoter (i.e. most likely to be active) and stable H3K4me3 has been associated with transcription initiation [19, 20] . Table I shows androgen globally decreased both histone markers. In comparison, hypoxia globally increased the number of histone marker binding sites. The locations of the transcription factors (AR, HIF) and the histone markers (H3K4me1, and H3K4me3) were analysed within the exons and introns of the seven genes identified in the gene expression analysis ( Supplementary Fig 3) . Neither AR nor HIF bound within the TWIST1 and IGFBP3 genes (data not shown). There were more AR, HIF, H3K4me1 and H3K4me3 binding sites in KCNN2 and PPFIBP2 compared to the other genes (Table II) .
These observations suggest that KCNN2 and PPFIBP2 are directly regulated by promoter proximal and intragenic recruitment of the AR and HIF1 whereas TWIST1 and IGFBP3 may be enhancer regulated. Indeed changes in IGFBP3 expression have been shown to be affected by and to affect the expression of a range of genes through long-range chromatin and interchromosomal interactions [21] . In addition, TWIST1 is known to function as a transcriptional driver of EMT. Consequently, although the number of genes we have identified as co-ordinately regulated by the AR and HIF1 is small in number their impact may be far-reaching.
Effect of TWIST1, KCNN2, PPFIBP2, JAG1, SPRED1, IGFBP3 and NDRG1 on prognosis
Five publically available prostatectomy gene expression cohorts were used to test the prognostic significance of the seven genes upregulated by androgen, stable HIF1a expression and hypoxia (Table III) . TWIST1 was the most prognostic with high expression associated with poor a prognosis in three cohorts. Five of the genes were prognostic in a single cohort and SPRED1 had no prognostic significance (Table III) . We further compared were globally decreased within the DNA following synthetic androgen R1881 treatment. In contrast hypoxia marginally increased the presence the two histone markers, it has previously been reported that hypoxia rapidly increases histone methylation independently of HIF [33] . Despite decreasing the prevalence of H3K4me3, the location of the histone marker within promoter regions was increased as a result of R1881 treatment and indicates enhanced transcriptional activity.
We found few HIF transcription factor binding sites within the introns and exons of the seven genes upregulated by androgen and HIF1a suggesting the HIF regulated expression of these genes is most likely driven by it binding to distal sites [34] . The greatest number of AR binding sites within the genes was observed with androgen treatment under normoxia, with a reduction in the number of AR binding sites under hypoxia. This decrease in AR binding sites under hypoxia was observed globally, possibly as a result of hypoxia induced conformational changes in the DNA which restrict the accessibility of AR binding sites.
Of the seven genes upregulated by both androgen and HIF TWIST1 was the most prognostic. Upregulated TWIST1 and AR expression have previously been reported in a castration resistant LNCaP mouse model, implicating crosstalk between epithelial mesenchymal transition and castration resistance [35] . TWIST1 was also shown to upregulate AR expression and to be upregulated in response to ADT [36] . The variability in prognostic significance between the cohorts may in part be due to use of different gene expression platforms. A further limitation is that most patients in the cohorts had primary prostate cancer treated by radical prostatectomy without hormone therapy and were mostly low and intermediate risk patients. Considering the seven genes identified in this study are upregulated by androgen, HIF1a and/or hypoxia it is hypothesized that they promote disease progression and development of CRPC and it would be interesting to look at the expression of these genes in high risk and advanced prostate cancer cohorts. As AR and HIF signaling axes are active in CRPC these seven genes are potential biomarkers of aggressive disease that might be useful to predict likely disease progression towards CRPC [37, 38] .
In this study the absence of HIF1a and endogenous androgen in vivo resulted in regression of tumor growth but HIF1a signaling could restore tumor growth in the absence of AR signaling. The data presented here indicate simultaneous therapeutic inhibition of the HIF1a and AR signaling pathways is a potential therapeutic strategy, as has previously been proposed [38] . We show that the oncogenic signaling pathways target the expression of different subsets of genes but both promote proliferation, tumor growth and disease progression. The relationship between the AR and HIF1a signaling pathways and their association with the development of CRPC could be exploited to identify predictive biomarkers of progression to CRPC and dual targeting of the AR and hypoxia/HIF1a should be further investigated for patients most at risk of developing CRPC. 
